Bollmann, L.M.; Skerhut, A.J.; Asfaha, Y.; Horstick, N.; Hanenberg, H.; Hamacher, A.; Kurz, T.; Kassack, M.U.
The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines. Int. J. Mol. Sci. 2022, 23, 13398.
https://doi.org/10.3390/ijms232113398
AMA Style
Bollmann LM, Skerhut AJ, Asfaha Y, Horstick N, Hanenberg H, Hamacher A, Kurz T, Kassack MU.
The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines. International Journal of Molecular Sciences. 2022; 23(21):13398.
https://doi.org/10.3390/ijms232113398
Chicago/Turabian Style
Bollmann, Lukas M., Alexander J. Skerhut, Yodita Asfaha, Nadine Horstick, Helmut Hanenberg, Alexandra Hamacher, Thomas Kurz, and Matthias U. Kassack.
2022. "The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines" International Journal of Molecular Sciences 23, no. 21: 13398.
https://doi.org/10.3390/ijms232113398
APA Style
Bollmann, L. M., Skerhut, A. J., Asfaha, Y., Horstick, N., Hanenberg, H., Hamacher, A., Kurz, T., & Kassack, M. U.
(2022). The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines. International Journal of Molecular Sciences, 23(21), 13398.
https://doi.org/10.3390/ijms232113398